LACOG 0801 - GLICO
A randomized open-label, phase II study of lapatinib/capecitabine or lapatinib/vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progressing after taxanes treatment.
Objective response rate (ORR)
This is a phase II, open-label, multicentric, international, randomized trial of lapatinb/capecitabine (control arm), lapatinib/vinorelbina (experimental) and lapatinib/gemcitabine (experimental) in ErbB2+ advanced or metastatic breast cancer patients that had progressed to taxanes.
Sample size: 142
LACOG Study Coordinators: Henry Gomez, Carlos Barrios
Status: Closed. Recruitment completed Dec 2012.
Sponsor: LACOG - Support GSK (Collaborative Groups: GAICO and GECOPERU)
ClinicalTrials.gov - NCT01050322
Phone: 55 51 3384 5334